Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Physiomics ( (GB:PYC) ) has shared an update.
Physiomics plc has announced that CEO Peter Sargent has agreed to extend his current agreement and will remain in his role through June 2026, providing continuity as the company navigates a period of significant internal change. The board is in ongoing discussions with Sargent about a possible longer-term role, underscoring his importance to the business and his contribution to a smooth management transition as the company formulates growth and expansion plans.
Chairman Nick Tulloch highlighted Sargent’s diligent oversight of operations and his skill in handling leadership changes, noting that his continued presence supports the new board as it refines strategy. The update signals stability in Physiomics’ leadership at a time when consistent execution may be critical for its positioning in the competitive market for model-informed drug development services.
Spark’s Take on PYC Stock
According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.
The score is held back primarily by weak financial performance: continued losses and persistent cash burn outweigh the benefit of a low-debt balance sheet and a 2025 revenue rebound. Technicals are moderately supportive with the price above major moving averages and a positive MACD, but elevated RSI suggests momentum may be stretched. Valuation is neutral-to-weak due to negative earnings and no dividend support.
To see Spark’s full report on PYC stock, click here.
More about Physiomics
Physiomics plc is a U.K.-listed mathematical modelling, data science and biostatistics specialist focused on supporting the development of new therapeutics and personalised medicine. The company combines modelling and simulation, bioinformatics and deep biology expertise, using proprietary tools such as its Virtual Tumour technology to streamline drug development for biotech and pharma clients including Merck KGaA, Astellas and Cancer Research UK.
Average Trading Volume: 6,834,664
Technical Sentiment Signal: Hold
Current Market Cap: £2.67M
Learn more about PYC stock on TipRanks’ Stock Analysis page.